The U.S. Food and Drug Administration (FDA) advised Waltham, Mass.-based FORUM Pharmaceuticals to halt its clinical trials of encenicline for Alzheimer’s disease yesterday. The FDA cited a small number of serious gastrointestinal (GI) side effects in the studies. As a result, FORUM halted the trial, discontinuing the medication and no new patients will be recruited […]

(Reuters Health) – Older adults with low vitamin D levels – and that accounts for most of them – may lose their memories and thinking abilities faster than those with normal vitamin D levels, researchers say. “We were not particularly surprised by our findings because there is a recent and growing literature on the associations […]

Resveratrol Impacts Alzheimer’s Disease Biomarker The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer’s disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol. Resveratrol is a naturally occurring compound found in foods such as […]

Possible Evidence For Human Transmission Of Alzheimer’s Pathology Amyloid beta pathology in the grey matter and blood vessel walls characteristic of Alzheimer’s disease (AD) and the related cerebral amyloid angiopathy (CAA) is observed in the brains of deceased patients who acquired Creutzfeldt–Jakob disease (CJD) following treatment with prion-contaminated human growth hormone. Although there is no […]

– Global Co-Development and Co-Commercialization Agreement in Alzheimer’s Disease With Novartis’ Phase 1/2a BACE Inhibitor as the Lead – Preventative Treatment Approach Directed at Genetically Predisposed Individuals at Risk of Developing Alzheimer’s Disease; Builds on Amgen’s Genetic Validation Strategy – Global Co-Development Agreement More Rapidly Advances Amgen’s Migraine Programs, Including AMG 334 in Phase 3 […]